Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chloe Kent

Reporter

London, UK

Chloe is an award-winning journalist who has specialized in health reporting throughout her career, with a particular focus on women's health and access to medicine. Before joining Generics Bulletin she worked for B2B publishing consortium Verdict, writing about medical technology and pharmaceuticals. Having graduated from the University of York, she went on to train as a journalist with the Press Association.

Latest From Chloe Kent

Ninth Canadian Jurisdiction Implements Biosimilar Switching Policy

Newfoundland and Labrador has become the ninth jurisdiction in Canada to implement a biosimilar switching policy for patients enrolled on its public health program.

Biosimilars Policy

Shared Savings Legislation Could Increase Medicare Biosimilar Access

Congressman Richard Hudson has introduced US legislation calling for a three-year ‘demonstration project’ into a shared savings payment scheme for biosimilar medicines provided through Medicare Part B.

Medicare Biosimilars

Canadian Generics Group Launches Cost-Saving Campaign

The CGPA is drawing attention to the cost savings Canadians can benefit from through the use of generic drugs via a PSA-style digital campaign.

Ad Campaigns Generic Drugs

Generic Pylera Leads Charge As Endo Aims To Fix Up Floundering Business

Endo has launched the first generic version of Allergan’s H. pylori treatment Pylera and plans to launch around 10 products from its sterile injectables and generics businesses this year.

Sales & Earnings Financing

California Snaps Up Civica For Biosimilar Insulin Initiative

Civica is set to provide biosimilar insulins to the state of California through its CalRx program, following approval from the US Food and Drug Administration.

Biosimilars Pricing Strategies

Shared Savings Legislation Could Increase Medicare Biosimilar Access

Congressman Richard Hudson has introduced US legislation calling for a three-year ‘demonstration project’ into a shared savings payment scheme for biosimilar medicines provided through Medicare Part B.

Biosimilars United States
See All
UsernamePublicRestriction

Register